

Evaluation of the changes in choroidal thickness in patients with central serous chorioretinopathy as measured by optical coherence tomography

Ragai Magdy Hatata, Mohamed Abdelhamid Nassif, Sherin Hassan Sadek

Department of Ophthalmology, Fayoum University, Fayoum 11435, Egypt

Correspondence to: Sherin Hassan Sadek. Department of Ophthalmology, Fayoum University, Fayoum 11435, Egypt. sh.sadek@gmail.com

Received: 2019-08-24 Accepted: 2020-01-17

Abstract

• **AIM:** To study the changes in choroidal thickness in central serous chorioretinopathy (CSCR) over a 3mo follow-up using spectral domain optical coherence tomography (SD-OCT).

• **METHODS:** This prospective study included 60 eyes, both eyes of 20 patients (mean age: 33.65 ± 5.24 y) with classic acute unilateral central serous chorioretinopathy and normal fellow eye and 20 eyes as healthy controls. Fluorescein angiography and OCT were done. The subfoveal choroidal thickness (SFCT), central macular thickness (CMT), 1000 μ m temporal and nasal to the centre of the fovea and the subretinal fluid were measured.

• **RESULTS:** There was a statistically significant difference in SFCT among the three groups at the three different locations. SFCT in eyes with CSCR (372.40 ± 34.39 μ m) was significantly greater than that in each of the unaffected fellow eyes (302.10 ± 8.9 μ m) and control eyes (279.80 ± 14.49 μ m) at the base line and after 3mo follow-up. The mean CMT in CSCR was 317 ± 141.86 μ m, with a statistically significant positive correlation between SFCT and CMT.

• **CONCLUSION:** The increase in the choroidal thickness at different locations as well as hyper-dilated and hyper-permeable vessels known as “pachychoroid” seems to play an important role in a broad spectrum of diseases that includes central serous chorioretinopathy.

• **KEYWORDS:** central serous chorioretinopathy; optical coherence tomography; choroidal thickness; pachychoroid

DOI:10.18240/ier.2021.01.06

Citation: Hatata RM, Nassif MA, Sadek SH. Evaluation of the changes in choroidal thickness in patients with central serous chorioretinopathy as measured by optical coherence tomography. *Int Eye Res* 2021;2(1):31-36

INTRODUCTION

Central serous chorioretinopathy (CSCR) is mostly a middle-aged disease that affects predominantly men. It is considered as a benign condition that ends almost in spontaneous complete resolution over a period of 3mo with good visual prognosis^[1].

CSCR is defined as an area of well-defined serous neurosensory retinal detachment in the posterior pole^[2] with leakage of subretinal fluid through the damaged retinal pigment epithelium (RPE)^[3].

The pathophysiology is not fully established and includes abnormal ion transport across the RPE as well as focal choroidal vasculopathy. Indocyanine green (ICG) angiography has shown the importance of the choroidal circulation to the pathogenesis of CSCR. Increased choroidal hyper-permeability and focal choroidal vascular compromise are believed to lead to secondary dysfunction of the overlying RPE^[4-5].

CSCR can be divided into 2 clinical presentations. Classic CSCR: one or two isolated leaking points at the level of the RPE as seen on fluorescein angiography (FA). Diffuse: characterized by neurosensory retinal detachment over areas of RPE atrophy and pigment mottling. Areas of granular hyperfluorescence that contain one or many subtle leaks are seen using FA as seen in diffuse retinal pigment epithelial dysfunction (e.g. diffuse retinal pigment epitheliopathy, chronic CSCR, decompensated RPE). “The retinal function imager RFI was used to detect a reduced flow velocity in the retinal venules, whilst the arterial flow velocity measurements were not significantly altered”^[6]. The baseline subfoveal and temporal CT may have a predictive value for chronicity^[7].

Progress in retinal imaging has led to the discovery of a variety of chorioretinal disorders. The use of enhanced depth imaging (EDI) and swept source OCT technologies have enabled a precise qualitative and quantitative analysis of the choroid^[8-9]. Pachychoroid a term that indicates abnormal and permanent increase in choroidal thickness. This entity usually occurs in eyes with central serous chorioretinopathy (CSCR) or CSCR-like features^[10]. Pachychoroid often shows dilatation of the large choroidal vessels compressing the overlying choriocapillaris and Sattler’s layer^[11].

In this study, we measured the choroidal thickness (CT), using spectral-domain optical coherence tomography (SD-OCT) in acute unilateral CSCR patients and compared it to the fellow unaffected eye and a healthy control group. We aimed to reveal the differences in the CT during the 3-month follow-up and whether these differences can be related to the disease as a step to understand the role of the choroid in pathogenesis and course of this disease. The increased choroidal thickness in the fellow eye at the time of the acute attack and its significant increase compared to the normal eye confirms the presence of pachychoroid in both eyes and can predict that the fellow eye is more prone to develop CSR than eyes of normal people.

SUBJECTS AND METHODS

Ethical Approval The study was approved by the ethical committee of Fayoum University. A consent of approval was signed by each patient. The study has followed the Tenets of the Declaration of Helsinki.

The study was prospective, included 60 eyes; both eyes of 20 patients and 20 eyes of healthy volunteers acting as controls during the period from September 2016 to March 2017. All patients received a comprehensive full ophthalmological examination that would lead to the diagnosis of CSCR including refraction, visual acuity, best corrected visual acuity, slit lamp biomicroscopy, intraocular pressure measurements, dilated fundus examination, fundus photography, fluorescein angiography and OCT.

Inclusion criteria; patients with classic CSCR with duration less than one month with normal fellow eye. Exclusion Criteria; Patients with bilateral CSCR, other cause of CSCR as CNV, pigment epitheliopathy and chronic CSCR, also patients receiving any medical treatment that may affect the course of the disease as corticosteroids as well as patients with refraction more than -2.00 dioptries. These cases were excluded to limit the analysis to only one pathological disease; acute CSCR and eliminate other factors that may affect the thickness. Choroidal thickness in different degrees of myopia is significantly thinner than that of normal control eyes^[12].

The study was subdivided into 3 groups: Group 1 included 20 eyes with CSCR; Group 2; 20 fellow eyes and Group 3; 20 eyes of normal controls.

A three-dimensional SD-OCT system, the RTVue XR Avanti with AngioVue software for OCTA (Optovue, Inc., Fremont, CA), was used to measure the subfoveal choroidal thickness and to measure central macular thickness CMT in eyes with CSCR. This system has optical resolution of 5 μ m depth resolution and 15 μ m beam spots with image sample rate of 2.9 μ m depth and 8 μ m transverse. Three-dimensional data were obtained using the Raster and HD line scan centred on the fovea, covering an area measuring 6 mm horizontal, 6 mm vertical, and 1.7 mm axial depth. The imaging data were

obtained using the split spectrum amplitude-decorrelation angiography (SSADA) software. The choroidal thickness was measured from the outer portion of the hyper reflective line corresponding to the RPE to the choroidoscleral junction at three different locations: At the centre of the fovea, 1000 μ m temporal to the centre of the fovea and 1000 μ m nasal to the centre of the fovea. The subretinal fluid was measured manually using callipers.

Statistical Analysis The collected data was organized, tabulated and statistically analyzed using SPSS software statistical computer package version 18 (SPSS Inc, USA). For quantitative data, the mean and standard deviation were calculated. Comparison between 2 study groups as regards age was done using Independent *t*-test. One-way analysis of variance (ANOVA) followed by least significance difference LSD (post hoc test) was performed to compare between the three eyes groups regarding values of Choroid thickness in different locations at different times. Within each group, dependent *t*-test was used to test the difference changes in choroid thickness in different locations at different times. Sex was described as frequencies (number of cases) and percentages; Chi-square test was used as a test of significance. For interpretation of results of tests of significance, significance was adopted at $P \leq 0.05$.

RESULTS

The study included 40 eyes of 20 patients and 20 eyes of healthy volunteers, with total of 60 eyes divided into 3 groups. The mean age of the patients was 33.65 ± 5.24 y; 15 males and 5 females. All patients suffered from acute, unilateral CSCR. All of them have shown complete recovery with disappearance of subretinal fluid except for 4 patients at the end of the follow up period.

At baseline, the mean subfoveal choroidal thickness of affected eyes (Group 1) was 372.40 ± 34.39 μ m after the 3-month follow-up period; the mean thickness was 337.0 ± 35.9 μ m with a statistically significant decrease ($P < 0.001$). At the temporal location the mean thickness was 353.00 ± 29.85 μ m and decrease to a mean of 318.4 ± 24.96 μ m at 3 months follow-up; a change that was statistically significant ($P < 0.001$). The mean thickness at the nasal location was 351.20 ± 29.98 μ m and decrease to a mean of 312.05 ± 17.01 μ m at 3 mo follow up with a statistically significant change ($P < 0.001$). Figure 1 shows the representative images of the group while Figure 2 shows the average choroidal thickness at each location.

In fellow eyes (group 2) at baseline, the mean subfoveal choroidal thickness was 302.10 ± 8.9 μ m after the 3-month follow-up period the mean thickness was 299.55 ± 8.7 μ m; a decrease that was statistically significant ($P < 0.001$). At the temporal location, the mean thickness was 283.55 ± 7.1 μ m and change to a mean of 287.75 ± 23.37 μ m at 3-month follow-up;




Figure 1 OCT of the affected eye showing measurements at the three locations (A); After 3mo follow-up (B); FFA showing the ink blot leaking point (C).

a change that was statistically insignificant ($P<0.408$). At the Nasal location the mean thickness was $280.60\pm7.18\ \mu\text{m}$ and decrease to a mean of $280.30\pm7.66\ \mu\text{m}$ at 3months follow-up; a change that was not statistically significant ($P<0.868$). The representative image of the group is shown in Figure 3 while Figure 4 demonstrates the average choroidal thickness at each location. Thickness of the choroid varied with location, with the maximum thickness at the centre of the fovea. There was statistically significant difference between groups 1 and 2 at the three different locations at time of presentation and at the end of the follow up period ($P<0.001$).

Healthy control group: the mean age of the control group was $31.35\pm4.23\text{y}$ (15 males, 5 females) with no history of ophthalmological complaints.

At baseline, the mean subfoveal choroidal thickness was $279.80\pm14.49\ \mu\text{m}$. After the 3-month follow-up period, the average thickness was $279.30\pm13.67\ \mu\text{m}$ a decrease that was not statistically significant ($P<0.415$). At the temporal location, the mean thickness was $272.75\pm16.17\ \mu\text{m}$ and decrease to $271.80\pm15.52\ \mu\text{m}$ at 3months follow-up; a change that was statistically insignificant ($P<0.081$). The mean thickness at the nasal location was $270.24\pm15.52\ \mu\text{m}$. It decreased to a mean of $269.40\pm15.96\ \mu\text{m}$ at 3months follow-up, a change that was not statistically significant ($P<0.077$). Figure 5 shows the representative images of the group while the average choroidal thickness at each location is shown in Figure 6.

There was a statistically significant difference in SFCT among the three groups at the three different locations. SFCT in eyes with CSCR was significantly greater than that in each of the unaffected fellow eyes ($P<0.001$) and normal control eyes ($P<0.001$) at the base line but with no statistically significant difference in SFCT between the unaffected fellow eyes and normal control eyes ($P>0.05$) at the end of follow up period (results are shown in Figure 7). The relation between the 3 groups at the base line and after 3mo follow up are shown in Table 1. There were no statically significant changes between the baseline and the follow up measurements in group 2 and 3 except for the CT at the temporal and nasal locations in the fellow eye that showed statistically significant decrease at the end of the follow up period ($P<0.05$).




Figure 2 Mean choroidal thickness at the three locations of the affected eyes.




Figure 3 Measurements at the three locations of the unaffected eye.




Figure 4 Mean choroidal thickness at different locations of the fellow eyes.




Figure 5 The measurements at the three locations in the control group.

The serous retinal detachment was manually measured in group 1 eyes with CSCR to determine whether there was a

Table 1 The measurements of the choroidal thickness among the three groups at the three locations and after 3months follow up (n=20)

Parameters	Group 1	Group 2	P	Group 1	Group 3	P	Group 2	Group 3	P
SFCT	372.40±34.39	302.10±8.9	<0.001	372.40±34.39	279.80±14.49	<0.001	302.10±8.9	279.80±14.49	0.002
SFCT after 3mo	337.0±35.9	299.55±8.7	<0.001	337.0±35.9	297.30±13.67	<0.001	299.55±8.7	297.30±13.67	0.755
Temporal	353.0±29.85	283.55±7.1	<0.001	353.0±29.85	272.75±16.17	<0.001	283.55±7.1	272.75±16.17	0.094
Temporal after 3mo	318.4±24.96	287.75±23.37	<0.001	318.4±24.96	271.80±15.52	<0.001	287.75±23.37	271.80±15.52	0.024
Nasal	351.20±29.98	280.60±7.18	<0.001	351.20±29.98	270.24±15.52	<0.001	280.60±7.18	270.24±15.52	0.106
Nasal after 3mo	312.05±17.01	280.30±7.00	<0.001	312.05±17.01	269.40±15.96	<0.001	280.30±7.00	269.40±15.96	0.017

Group 1: Affected eyes; Group 2: Fellow eyes; Group 3: Healthy control eyes; SFCT: Subfoveal choroidal thickness.




Figure 6 Mean choroidal thickness of the healthy control group at different locations.




Figure 7 The measurements of the choroidal thickness among the three groups at the three locations after 3months follow up.

correlation between SFCT and CMT. The mean CMT in eyes with CSCR was 317±141.86 µm with a range from 130 to 619 µm, and there was a statistically significant positive correlation between SFCT and CMT in these eyes ($P<0.001$).

DISCUSSION

The study aimed to evaluate the role of choroid in the pathogenesis of the CSCR through measuring choroidal thickness in the subfoveal area and whether an increase in the thickness can be related to the disease. This was done by measuring the thickness of the affected eye and compared it to the fellow unaffected eye and to the normal choroidal thickness through a healthy control group using the OCT. Different levels of visual function may be related to structural OCT changes, and OCT findings could be important parameters for both follow-up and treatment^[13].

In this study, the mean SFCT of eyes with CSCR was significantly greater than that in the unaffected fellow eyes and in normal control eyes, as well as between unaffected fellow eyes and normal control eyes and between the fellow and normal eyes. These results matched with Chung *et al*^[14] where the subfoveal choroidal thickness and the thickness of Haller layer were greater in the affected and the unaffected fellow

eyes compared to normal eyes. “Regatieri *et al*^[15], reported that Choroid in older patients; older than 60y old with active CSCR was thicker than the choroid in age-matched normal eyes. The results of the current study were also in agreement with other studies; “Goktas^[3], Dang *et al*^[16], and Yang *et al*^[17], concluding that the mean SFCT in symptomatic eyes with CSCR is significantly greater than that in fellow eye and control group. Other studies demonstrated that SFCT was increased in CSCR eyes, as well as in unaffected fellow eyes, thus suggesting that CSCR may be a bilateral disorder. The frequency of the bilaterality is reported at 20% to 40%^[18-19]. The data of Brandl *et al*^[20] and associates indicated that after 3mo, normalisation of choroidal thickness was not yet completed.

In fellow eyes (group 2; unaffected eyes), the mean subfoveal choroidal thickness at baseline was 302.10±8.9 µm while after the 3-month follow-up period the mean thickness was 299.55±8.7 µm; a decrease that was statistically significant ($P<0.001$). That what statistically significant is not necessarily clinically significant. The sample size and random variation play an important role in whether a result is statistically significant or not and, together with the effect size, whether the study is “powered” to detect statistical differences^[21]. In our study, although the observed differences were tiny, the results were statistically significant. These findings may be attributed to the low variability of the individual values around their average, which can be identified as low standard deviation.

While Jirarattanasopa *et al*^[22] found the macular choroidal thickness in unaffected fellow eyes less than that the CSCR eyes but it did not differ from normal control eyes. Dansingani *et al*^[23] in another study by using swept-source OCT en face imaging of patients with Pachychoroid found dilated choroidal vessels in eyes without manifest pathology, projecting that pachychoroid is a bilateral phenomenon with a systemic basis. The current study measured the SFCT at three different locations, at the center of the fovea, 1000 µm temporal and 1000 µm nasal to the center of the fovea and the measurements showed significant increase in the thickness in eyes with CSCR as compared to the unaffected and control eyes. These results were in agreement with Kim *et al*^[24] who measured the choroidal thicknesses at five points (centre of the fovea,

500 μm , 1000 μm and 1500 μm temporal and nasal to the fovea) and showed them significantly higher for CSCR eyes than for controls at all locations. Manabe *et al*^[25], measured the choroidal thickness at a wider area by using inner and outer circle of the macula in active chronic CSCR and found them significantly greater than in normal controls.

The current study evaluated the SFCT after three months follow up which have seen almost spontaneous total resolution in 16 cases and a near total resolution in the other 4 cases. In the three groups; a decrease in the choroidal thickness at the three locations was noted but was only statistically significant in the group with the affected eye (group 1) which suggest the basic role of the choroidal circulation in the pathogenesis of CSCR. A follow-up study by Kang *et al*^[26] of CSCR eyes found a decrease by about -9% in the SFCT after a spontaneous resolution but not returning to normal values suggesting a threshold of choroidal thickness above which accumulation of subretinal fluid starts to occur.

In the current study measurements of the choroidal thickness were taken from 10 *a.m.* to 2 *p.m.* to avoid the circadian pattern that may affect the outcome of study, as previous studies showed that choroidal thickness presents higher level at night and lower level during the day in young adults^[27-29].

The current study also investigated the correlation between SFCT and CMT, including elevation of the serous retinal detachment, in eyes with CSCR and found a significant positive correlation. Iijima *et al*^[5], instead, studied the correlation of SFCT and subretinal fluid volume, which was estimated using a built-in segmentation-modifying tool of SD-OCT, and found no association between these two parameters in eyes with acute CSCR. Therefore, he suggested that formation of subretinal fluid might not solely be associated with choroidal vasculature and that some additional factors such as RPE dysfunction could have a role in the pathogenesis of CSCR, which might need further studies to clarify.

Gołbiewska *et al*^[30] reported that CT was increased in eyes with chronic CSCR, but without any correlation with CNV occurrence; therefore, CT cannot be considered as a predictor of CNV occurrence. Optical coherence tomography angiography (OCTA) detected CNV more frequently than other imaging modalities.

The results of this study were limited by the small number of cases as well as the manual measurement of the choroidal thickness as no automatic measures of mapping were available. A larger group of patients and a longer period of follow up as well as a more advanced way in measuring the choroidal thickness would have added to our study. However, the accurate and reliable measurements of the choroidal thickness and the changes through the study that occurs during the process of the disease may be of great value in helping

researchers to know more about the actual pathological nature of the disease.

The increase in the choroidal thickness as well as hyper-dilated and hyper-permeable vessels known as “pachychoroid” seems to play an important role in a broad spectrum of diseases that includes CSCR.

ACKNOWLEDGEMENTS

Conflicts of Interest: Hatata RM, None; Nassif MA, None; Sadek SH, None.

Peer Review File: Available at: http://ier.ijo.cn/gjykier/ch/reader/download_attache_file.aspx?seq_id=20210326104744001&flag=1&journal_id=gjykier&year_id=2021&issue=1

REFERENCES

- Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. *Curr Opin Ophthalmol* 2011;22(3):166-173.
- Kim DY, Joe SG, Yang SJ, Lee JY, Kim JG, Yoon YH. The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy. *Korean J Ophthalmol* 2015;29(3):160-167.
- Goktas A. Correlation of subretinal fluid volume with choroidal thickness and macular volume in acute central serous chorioretinopathy. *Eye (Lond)* 2014;28(12):1431-1436.
- Okushiba U, Takeda M. Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography. *Nippon Ganka Gakkai Zasshi* 1997;101(1):74-82.
- Iijima H, Iida T, Murayama K, Imai M, Gohdo T. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. *Am J Ophthalmol* 1999;127(4):477-478.
- Beutelspacher SC, Serbecic N, Barash H, Burgansky-Eliash Z, Grinvald A, Jonas JB. Central serous chorioretinopathy shows reduced retinal flow circulation in retinal function imaging (RFI). *Acta Ophthalmol* 2011;89(6):e479-e482.
- Yumusak E, Gokcinar NB, Ornek K. Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy. *Medicine (Baltimore)* 2018;97(43):e12885.
- Spaide RF, Koizumi H, Pozonni MC. Enhanced depth imaging spectral-domain optical coherence tomography. *Am J Ophthalmol* 2008;146(4):496-500.
- Potsaid B, Baumann B, Huang D, Barry S, Cable AE, Schuman JS, Duker JS, Fujimoto JG. Ultrahigh speed 1050nm swept source/Fourier domain OCT retinal and anterior segment imaging at 100,000 to 400,000 axial scans per second. *Opt Express* 2010;18(19):20029-20048.
- Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F. Pachychoroid: an inherited condition? *Retina* 2015;35(1):10-16.
- Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. *Retina (Philadelphia, Pa)* 2013;33(8):1659-1672.
- El-Shazly AA, Farweez YA, ElSebaay ME, El-Zawahry WMA. Correlation between choroidal thickness and degree of myopia

- assessed with enhanced depth imaging optical coherence tomography. *Eur J Ophthalmol* 2017;27(5):577-584.
- 13 Malik A, Gupta A, Mithal C, Gupta V, Gupta Y. Central serous chorioretinopathy: correlation of structural changes on optical coherence tomography with visual outcomes. *Delta J Ophthalmol* 2017;18(1):37.
- 14 Chung YR, Kim JW, Kim SW, Lee K. Choroidal thickness in patients with central serous chorioretinopathy: assessment of haller and sattler layers. *Retina* 2016;36(9):1652-1657.
- 15 Regatieri CV, Novais EA, Branchini L, Adhi M, Cole ED, Louzada R, Lane M, Reichel E, Duker JS. Choroidal thickness in older patients with central serous chorioretinopathy. *Int J Retina Vitreous* 2016;2:22.
- 16 Dang YL, Sun XF, Xu YS, Mu YL, Zhao ML, Zhao J, Zhu Y, Zhang C. Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathy. *Ther Clin Risk Manag* 2014;10:37-43.
- 17 Yang LH, Jonas JB, Wei WB. Choroidal vessel diameter in central serous chorioretinopathy. *Acta Ophthalmol* 2013;91(5):e358-e362.
- 18 Kitmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. *Ophthalmology* 2008;115(1):169-173.
- 19 Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. *Clin Exp Ophthalmol* 2013;41(2):201-214.
- 20 Brandl C, Helbig H, Gamulescu MA. Choroidal thickness measurements during central serous chorioretinopathy treatment. *Int Ophthalmol* 2014;34(1):7-13.
- 21 Skelly AC. Probability, proof, and clinical significance. *Evid Based Spine Care J* 2011;2(4):9-11
- 22 Jirattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, Matsumoto A, Yoshimura N. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. *Ophthalmology* 2012;119(8):1666-1678.
- 23 Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. *Retina* 2016;36(3):499-516.
- 24 Kim SW, Oh J, Kwon SS, Yoo J, Huh K. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. *Retina* 2011;31(9):1904-1911.
- 25 Manabe S, Shiragami C, Hirooka K, Izumibata S, Tsujikawa A, Shiraga F. Change of regional choroid thickness after reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy. *Am J Ophthalmol* 2015;159(4):644-651.
- 26 Kang NH, Kim YT. Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy. *Eye (Lond)* 2013;27(3):387-391.
- 27 Seidel G, Hausberger S, Herzog SA, Palkovits S, Pöschl EM, Wackernagel W, Weger M. Circadian macular volume changes in the healthy human choroid. *Am J Ophthalmol* 2015;159(2):365-71.e2.
- 28 Zhao M, Yang XF, Jiao X, Lim A, Ren XT, Snellings T, Liu NP. The diurnal variation pattern of choroidal thickness in macular region of young healthy female individuals using spectral domain optical coherence tomography. *Int J Ophthalmol* 2016;9(4):561-566.
- 29 Kinoshita T, Mitamura Y, Shinomiya K, Egawa M, Iwata A, Fujihara A, Ogushi Y, Semba K, Akaiwa K, Uchino E, Sonoda S, Sakamoto T. Diurnal variations in luminal and stromal areas of choroid in normal eyes. *Br J Ophthalmol* 2017;101(3):360-364.
- 30 Gołębiewska J, Brydak-Godowska J, Moneta-Wielgoś J, Turczyńska M, Kęcik D, Hautz W. Correlation between choroidal neovascularization shown by OCT angiography and choroidal thickness in patients with chronic central serous chorioretinopathy. *J Ophthalmol* 2017;2017:3048013.